kabutan

HEALIOS Extends Gains on Official Approval of Regenerative Medicine Manufacturing Facility Subsidy◇

Mon Mar 30, 2026 10:11 am JST Catalyst

HEALIOS K.K. <4593> continued to rise. Following the close of trading on the 27th, the company announced that it has officially been approved to receive a subsidy from the Ministry of Economy, Trade and Industry for "Manufacturing Facility Investment Support for Regenerative Medicine, Cell Therapy, and Gene Therapy," which is being viewed as positive news.

The company plans to receive approximately \7 billion in subsidies to develop a manufacturing facility for its contract development and manufacturing organization (CDMO) business for regenerative medicine products. A cell processing and manufacturing facility (CPC) will be established at "DP-Lab KOBE" (Chuo-ku, Kobe City) operated by DAIWA HOUSE INDUSTRY CO., LTD. <1925>. In the future, the company intends to accept contract development and manufacturing orders from domestic and overseas pharmaceutical companies, as well as manufacture its own somatic stem cell regenerative medicine product (development code "HLCM051") for acute respiratory distress syndrome (ARDS), trauma, and acute cerebral infarction, promoting it as a CDMO business.

Note: The "◇" symbol at the end of the title indicates that the article contains multiple stock issues.

Source: MINKABU PRESS

Related Articles